Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

3 results
Filters applied: . Clear all
Page 1
Ruxolitinib is more effective than other JAK Inhibitors to treat VEXAS Syndrome: a retrospective multi center study.
Heiblig M, Ferrada MA, Koster MJ, Barba T, Gerfaud-Valentin M, Mékinian A, Coelho H, Fossard G, Barraco F, Galicier L, Bienvenu B, Hirsch P, Vial G, Boutin AB, Galland J, Le Guenno G, Bigot A, Warrington KJ, Kermani TA, Grayson PC, Patel BA, Beck D, Jamilloux Y, Fenaux P, Sujobert P. Heiblig M, et al. Blood. 2022 May 24:blood.2022016642. doi: 10.1182/blood.2022016642. Online ahead of print. Blood. 2022. PMID: 35609174 No abstract available.